Compare Moderna, Inc. (MRNA) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? Moderna, Inc. trades at $214.72 (market cap $78.65B), while Vanguard Total International Stock Index Fund ETF trades at $84.6 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 8.5× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Vanguard Total International Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| MRNA | VXUS | |
|---|---|---|
Market Cap | $78.65B | $665.70B |
Volume | 37,373,437 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $203.46 | $88.41 |
52-Week Low | $22.36 | $72.17 |
Typical Hold Time | 59 Days | 55 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
VXUS, the Vanguard Total International Stock ETF, trades at $84.56, down 0.26% with a bearish technical signal. The ETF provides diversified exposure to international developed and emerging markets outside the US. Recent news highlights its role in portfolio diversification and institutional buying interest, though technical indicators show selling pressure across moving averages and oscillators.
The outlook for VXUS hinges on international market performance relative to US equities, with potential for long-term growth diversification. Risks include currency fluctuations and regional economic volatility. Institutional accumulation suggests confidence in international equity exposure as a strategic portfolio component.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
